A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

This study tests a combination of lisaftoclax (APG-2575), a new drug that helps cancer cells die, plus azacitidine (a standard drug for blood cancers) in older or less healthy adults with newly diagnosed acute myeloid leukemia (AML) who are not fit for intensive chemotherapy. **You may be eligible if...** - You are 70 or older with ECOG score 0–2, or between 18 and 70 with ECOG score 0–3 and unfit for standard chemotherapy - You have a new diagnosis of AML and have not received prior treatment for blood disorders - You have adequate kidney and liver function - You are able to take oral medications **You may NOT be eligible if...** - You have a special subtype of AML called acute promyelocytic leukemia (APL) or BCR-ABL1-positive AML - Your leukemia has spread to your brain and spinal fluid - You have an active uncontrolled infection - You have significant heart failure (New York Heart Association Class 3 or higher) - Your white blood cell count is above 30 billion cells per liter Talk to your doctor to see if this trial is right for you.